SHANGHAI, Jan. 29, 2019 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, today announced that one of its leading drug candidates, humanized GPC3-CAR-T cell for the treatment of patients suffering from GPC3-positive solid tumors, has received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA). This marks China's first IND clearance for CAR-T cells against solid tumors.